Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.


Division of Gynecologic Oncology, Department of Obstetrics Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA. Electronic address: [Email]


Most women with advanced epithelial ovarian cancer develop recurrent disease, despite maximal surgical cytoreduction and adjuvant platinum-based chemotherapy. In observational studies, secondary cytoreductive surgery has been associated with improved survival; however its use is controversial, because there are concerns that the improved outcomes may reflect selection bias rather than the superiority of secondary surgery.


chemotherapy,cytoreductive surgery,recurrent ovarian cancer,